These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 701018)

  • 41. Experimental studies of the use of DTPA and other agents to limit the systemic burden of plutonium after wound contamination.
    Harrison JD; David AJ
    Radiat Res; 1979 Mar; 77(3):534-46. PubMed ID: 441257
    [No Abstract]   [Full Text] [Related]  

  • 42. Should Zn-DTPA replace Ca-DTPA for decorporation of radionuclides in man.
    Health Phys; 1976 Sep; 31(3):290-1. PubMed ID: 185166
    [No Abstract]   [Full Text] [Related]  

  • 43. Zn-DTPA administered by slow-release implant.
    Calder SE; Taylor GN; Lloyd RD; Petersen RV; Atherton DR; Mays CW
    Health Phys; 1978 Dec; 35(6):785-90. PubMed ID: 738883
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of ascorbate ions in DTPA treatment after contamination by mixed plutonium dioxide-sodium burning products.
    Métvier H; Masse R; Nolibé D; Nénot JC; Lafuma J
    Health Phys; 1977 May; 32(5):450-2. PubMed ID: 881345
    [No Abstract]   [Full Text] [Related]  

  • 45. DTPA treatment schedules for decorporation of 239Pu from simulated wounds.
    Gemenetzis E; Volf V
    Health Phys; 1977 Jun; 32(6):489-92. PubMed ID: 881349
    [No Abstract]   [Full Text] [Related]  

  • 46. Effectiveness of DTPA therapy when administered intragastrically or intraperitoneally to remove Pu from adult or neonatal rats.
    Sullivan MF; Ruemmler PS
    Health Phys; 1986 Nov; 51(5):641-6. PubMed ID: 3771225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Report on a plutonium-239 contaminated lacerated and incised wound].
    Ohlenschläger L; Schieferdecker H
    Strahlentherapie; 1973 Dec; 146(6):675-84. PubMed ID: 4792264
    [No Abstract]   [Full Text] [Related]  

  • 48. Developing a physiologically based approach for modeling plutonium decorporation therapy with DTPA.
    Kastl M; Giussani A; Blanchardon E; Breustedt B; Fritsch P; Hoeschen C; Lopez MA
    Int J Radiat Biol; 2014 Nov; 90(11):1062-7. PubMed ID: 24844369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A measure of the effectiveness of DTPA chelation therapy in cases of plutonium inhalation and plutonium wounds.
    Schofield GB; Lynn JC
    Health Phys; 1973 Mar; 24(3):317-26. PubMed ID: 4691640
    [No Abstract]   [Full Text] [Related]  

  • 50. The CONRAD approach to biokinetic modeling of DTPA decorporation therapy.
    Breustedt B; Blanchardon E; Bérard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
    Health Phys; 2010 Oct; 99(4):547-52. PubMed ID: 20838097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Research in the complexon series. I. Detoxicant capacity of Ca-DTPA in experimental chronic plutonium poisoning in rats. II. Influence of the repeated intravenous administration of Ca-DTPA on the elimination of trace elements in rats. 3. Preliminary results of the study, in rats, of the modalities of calcium elimination after Ca45-DTPA injection].
    Truhaut R; Boudène C; Lutz M
    Ann Biol Clin (Paris); 1966; 24(3):419-39. PubMed ID: 5932716
    [No Abstract]   [Full Text] [Related]  

  • 52. Predicting plutonium decorporation efficacy after intravenous administration of DTPA formulations: Study of pharmacokinetic-pharmacodynamic relationships in rats.
    Phan G; Le Gall B; Deverre JR; Fattal E; Bénech H
    Pharm Res; 2006 Sep; 23(9):2030-5. PubMed ID: 16951998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decorporation of 241Am in beagles by DTPA.
    Lloyd RD; Mc Farland SS; Taylor GN; Williams JL; Mays CW
    Radiat Res; 1975 Apr; 62(1):97-106. PubMed ID: 235147
    [No Abstract]   [Full Text] [Related]  

  • 54. Reducing the cancer risk of 239Pu by chelation therapy.
    Jones CW; Mays CW; Taylor GN; Lloyd RD; Packer SM
    Radiat Res; 1986 Sep; 107(3):296-306. PubMed ID: 3749464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation.
    Phan G; Herbet A; Cholet S; Benech H; Deverre JR; Fattal E
    J Control Release; 2005 Dec; 110(1):177-88. PubMed ID: 16257469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Plutonium-329 metabolic characteristics during the separate and combined administration of an iron preparation and DTPA].
    Shvydko NS; Rushonik SI; Popov DK; Likhtarev IA
    Radiobiologiia; 1981; 21(6):868-72. PubMed ID: 7323274
    [No Abstract]   [Full Text] [Related]  

  • 57. A study of translocation dynamics of plutonium and americium from simulated puncture wounds in beagle dogs.
    Bistline RW; Watters RL; Lebel JL
    Health Phys; 1972 Jun; 22(6):829-31. PubMed ID: 5084017
    [No Abstract]   [Full Text] [Related]  

  • 58. [Effect of liposome-encapsulated pentacin on plutonium-239 excretion].
    Il'in LA; Ivannikov AT; Altukhova GA; Parfenova IM; Chelysheva TV
    Radiobiologiia; 1989; 29(2):197-201. PubMed ID: 2717714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental background for prompt treatment with DTPA of 239Pu-contaminated wounds.
    Volf V
    Health Phys; 1974 Sep; 27(3):273-7. PubMed ID: 4436049
    [No Abstract]   [Full Text] [Related]  

  • 60. The use of Ca-DTPA as a treatment for plutonium inhaled in mixed oxide aerosols of plutonium and sodium.
    Stather JW; Rodwell P
    Health Phys; 1980 Nov; 39(5):801-5. PubMed ID: 7204032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.